0
Daewoong Pharm
Daewoong Pharmaceutical Co., Ltd (Korean is a Seoul, South Korea-based bioengineering company operating as a subsidiary of Daewoong Co., Ltd., a global health care group. Daewoong Pharmaceutical primarily engages in the manufacture of pharmaceutical products in South Korea, including prescription and over-the-counter healthcare products.
Established in 1945, Daewoong Pharmaceutical Co., Ltd. has the largest prescription drug sales in Korea and envisions itself to become a top 50 global healthcare company by 2020.
In addition to its product portfolio, which includes 15 blockbuster products, Daewoong has built strong core competency for new drug development and has cultivated a cooperative culture for collaboration with global partners.
In the future, Daewoong will expand its global business with its foreign branches and global partners and become a global healthcare group which contributes to improving the quality of life for people worldwide.
Daewoong Pharmaceutical, a public South Korean pharmaceutical company that develops, produces and sells medicines worldwide, today announced that the US Food and Drug Administration (FDA) approved the application for phase I clinical trials for DWP213388, a new candidate drug for the treatment of autoimmune diseases, iron.
Seng-ho Jong, CEO of Daewoong Pharmaceutical, said: «Daewoong Pharmaceutical plans to lead the development of various new drugs such as DWP213388, in collaboration with global licensees for patients with autoimmune diseases». lives of many patients around the world who suffer from lack of healing».
The planned phase 1 clinical trial will be a double-blind, randomized, placebo-controlled, single-dose and multiple-dose study involving 80 healthy volunteers. It will assess the safety, pharmacokinetics and pharmacodynamics of DWP213388 as a new strategy for the treatment of autoimmune diseases. The study is expected to begin in the second half of 2022 in the United States.
Unlike modern treatments, which are usually limited to inhibiting only B- or T-cells, DWP213388 is a double target inhibitor, simultaneously inhibiting B- and T-cells, and thus has a large potential for efficacy, than traditional treatments with only one effect. It selectively inhibits both Bruton tyrosine kinase (BTK) and interleukin-2-induced T cell kinase (ITK). Daewoong has shown that this dual activity is safe and effective for preventing or reducing autoimmune diseases in a number of pre-clinical models.
According to Research and Markets, the global market for the treatment of autoimmune diseases is growing at an annual average of 4.2% and is expected to reach $153 billion (around 200 trillion won) by 2025.